NC-SYNTERACT
4.2.2020 13:02:08 CET | Business Wire | Press release
Synteract , an innovative CRO partnering with biotech and pharma companies to bring new medicines to market, has acquired Clindata’s human health biometrics division to meet market demand for more adaptable biometrics services solutions. This acquisition extends Synteract’s existing global footprint into Asia Pacific and Africa, and offers another core biometrics services hub, complementary to those it operates in Europe and the U.S.
Clindata , with offices in Bloemfontein, South Africa, and Colombo, Sri Lanka, is a biometrics Clinical Research Organization, offering biostatistics, programming and data management services across all phases of drug development. Clindata’s Veterinary division will continue to operate under the Clindata name, independently from Synteract, while the Human Health Biometrics division will combine with Synteract. The combination of Clindata’s experienced team of biometrics professionals with that of Synteract’s further enhances Synteract’s biometrics capabilities as part of its integrated, full-service program; dedicated FSP solution , or as a standalone biometrics service to augment clients’ in-house capabilities.
“Like Synteract, Clindata is known for high quality service delivery, collaboration, agility and expertise of its teams,” says Synteract CEO Steve Powell . “Innovative changes in biometrics are transforming the ways in which clinical study data is collected, integrated and analyzed. Rich patient data gives researchers insights into disease progression and response to therapy in ways we have not seen before. This is an exciting time to be adding even more expertise to our teams and will allow us to deliver global biometrics services covering every time-zone.”
With a wealth of data management, CDISC, biostatistics and SAS experience, the Clindata team have significant experience running Phase I-IV studies across the complementary therapeutic areas of Synteract. Clindata CEO, Theo Erasmus, adds, “With our combined biometrics capabilities, clients will benefit from a complete service offering incorporating all data components from research, advice on study design, document planning to PK analyses and results interpretation, as well as global capabilities, all provided by one integrated CRO. We are glad to be joining Synteract and creating a world class delivery team.”
Synteract is a portfolio company of Amulet Capital Partners, LP. Financial terms are not being disclosed.
About Synteract
“Bringing Clinical Trials to Life ” represents Synteract’s commitment to engage with drug developers, patients, investigators, and regulatory experts, to bring insights to action and make better therapies a reality. Synteract supports biotech and pharma companies across all phases of drug development with multi-disciplinary teams and deep expertise. Synteract has conducted nearly 4,000 studies on six continents and has contributed to more than 240 product approvals. Synteract offers notable depth of expertise in oncology, dermatology, general medicine, neuroscience, pediatrics, and rare and orphan diseases. Connect on LinkedIn and Twitter .
About Clindata
Founded in 2012, Clindata is a Contract Research Organization (CRO) based in South Africa. The Clindata core team of experienced, dedicated staff has worked for in the CRO and health industry for many years. We bring a wealth of Data Management, CDISC, Biostatistics and SAS experience. Our team members have significant experience gained from working on studies of various phases and throughout an array of therapeutic areas.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200204005231/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Linnea Achieves CEP Certification for Cannabidiol Isolate3.3.2026 08:25:00 CET | Press release
Linnea is proud to announce that its Cannabidiol (CBD) Isolate has been granted a Certificate of Suitability to the European Pharmacopoeia (CEP). The CEP serves to attest that the quality of an active pharmaceutical ingredient (API) is adequately controlled by the monographs of the European Pharmacopoeia, ensuring its safety, quality and conformity for use in medicinal products in Europe. Issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM), the CEP represents an independent validation of consistency, safety, and regulatory compliance for the European market. This consequently simplifies the marketing authorization (MA) process for new medicines, as a detailed evaluation of the active substance by regulatory authorities is not required. This milestone represents a significant achievement for the company and reinforces its commitment to delivering consistent and high-quality cannabinoid ingredients. The certification provides customers and partners with as
Quectel Introduces FGH200M Wi-Fi HaLow Module for massive IoT Deployments3.3.2026 08:00:00 CET | Press release
Quectel Wireless Solutions, a global end-to-end IoT solutions provider, today announces the launch of the FGH200M long range, low power Wi-Fi HaLow module. Based on the Morse Micro MM8108 chipset and operating in the sub-1GHz license exempt frequency band, the module delivers enhanced penetration and broader coverage, over a range of approximately 1km, while supporting low power consumption and large-scale device connectivity. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260302200601/en/ Quectel introduces FGH200M Wi-Fi HaLow module for massive IoT deployments The FGH200M module adopts the IEEE 802.11ah wireless networking protocol, also known as Wi-Fi HaLow, operating in the license-exempt Sub-1GHz spectrum. Designed to meet the evolving requirements of IoT connectivity, the FGH200M delivers extended Sub-1GHz signal coverage, enabling reliable device control at distances of up to one kilometer. “We’re excited to unveil th
Quectel Expands Small Cell Antennas Portfolio With Five New Products3.3.2026 08:00:00 CET | Press release
Quectel Wireless Solutions, a global end-to-end IoT solutions provider, has introduced five new small cell antennas to add further functionality and provide greater flexibility and choice for customers designing and implementing small cell deployments. The new antennas bring an additional range of form factors, mounting options and performance characteristics to the Quectel antenna range. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260302915004/en/ Quectel expands small cell antennas portfolio with five new products “Whether you’re looking for an antenna to support critical wireless communications, dense stadium usage scenarios or ultimate capacity, these five new Quectel antennas have been designed to meet your needs,” says David Wei, Antenna Product Head, Quectel Wireless Solutions. “The new antennas augment our already comprehensive range of antennas, bring further choice and add capabilities for developers and enginee
Meiji Seika Pharma’s Morcamilast (ME3183) was Granted Orphan Medicinal Product Designation by the European Commission for Palmoplantar Pustulosis3.3.2026 02:00:00 CET | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that morcamilast (proposed international nonproprietary name; development code: ME3183), a selective phosphodiesterase-4 (PDE4) inhibitor, has been granted orphan medicinal product designation by the European Commission (EC) for the treatment of palmoplantar pustulosis (PPP). Palmoplantar pustulosis is a chronic inflammatory disease characterized by the development of multiple sterile pustules on the palms and soles. Patients often experience pain and pruritus of the skin, and the condition can be accompanied by nail involvement and joint pain. Because lesions on the palms are visible to others and lesions on the soles can cause pain while walking, daily functioning can be significantly restricted, leading in a substantial reduction in quality of life. PPP has a pathophysiology distinct from psoriasis and pustular psoriasis, and treatment can be challenging, unde
IFF Completed the Divestiture of Soy Crush, Concentrates and Lecithin Businesses2.3.2026 22:15:00 CET | Press release
IFF (NYSE: IFF) today announced that it has successfully completed the previously announced divestiture of its soy crush, concentrates and lecithin businesses to Bunge. This transaction does not include IFF’s soy isolates business. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in taste, scent, food ingredients, health and biosciences, we’re innovating for the future. Every day, we deliver groundbreaking, sustainable solutions that elevate products people love — advancing wellness, delighting the senses and enhancing the human experience. Learn more at iff.com, LinkedIn, Instagram and Facebook. © 2026 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved. View source version on businesswire.com: https://www.businesswire.com/news/home/20260302231096/en/
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom